The hypofunctional effect of P335L single nucleotide polymorphism on SSTR5 function.
BACKGROUND
Somatostatin receptor subtype 5 (SSTR5) mediates the inhibitory effect of somatostatin on insulin expression/secretion and cell proliferation. A number of single nucleotide polymorphisms (SNPs) of SSTR5 have been identified, including P335L, a nonsynonymous SNP located in the protein C-terminal region and encrypted by the codon CCG (proline) or the codon CTG (leucine). In the present study we sought to determine the distribution of the SSTR5 P335L SNP in a cohort of pancreatic cancer patients and whether the P335L SNP affected cellular function of SSTR5 in human pancreatic cancer.


METHODS
The P335L germline genotype of 246 patients with pancreatic cancer (213 Caucasians, 16 Hispanics, and 17 African Americans) and 17 human pancreatic cell lines was determined with the TaqMan SNP Genotyping assay. Human SSTR5 leucine variant (L335) was generated by performing site-directed mutagenesis using SSTR5 proline variant (P335) as a template. Transient transfections were performed in HEK293, Mia PaCa-2, and β-TC-6 cells using Lipofectamine 2000. The expression of SSTR5 L335 was determined with a mouse monoclonal anti-SSTR5 L335 antibody generated in our laboratory. The cell proliferation rate was measured by performing MTS assays. Insulin concentration was measured by performing ELISA assays.


RESULTS
Genotyping of the patients' blood indicated that the frequency of the T allele (CT and TT genotypes) in codon 335 of SSTR5 in Caucasians, Hispanics, and African Americans was 52, 69, and 35%, respectively, which was race-dependent. Statistical analysis indicated that association between the frequency of the T allele and the existence of pancreatic cancer in each race missed significance perhaps due to limited sample size. In 17 tested human pancreatic cancer cell lines, 5 (Capan-2, HPAF-II, Panc03.27, Panc-1, and -3) were homozygous (TT genotype) and 9, including Mia PaCa-2, were heterozygous (CT genotype). Overexpression of SSTR5 L335 in Mia PaCa-2 cells enhanced cell proliferation compared to overexpression of SSTR5 P335. Overexpression of SSTR5 P335 enhanced the inhibitory effect of SSTR5 agonist RPL-1980 on cell proliferation of Mia PaCa-2 cells and glucose-stimulated insulin secretion from mouse insulinoma cells, while overexpression of SSTR5 L335 blocked the inhibitory effect of RPL-1980. Overexpression of SSTR5 L335 enhanced PDX-1 expression in Mia PaCa-2 cells. A specific monoclonal antibody was generated to detect SSTR5 P335L.


CONCLUSIONS
SSTR5 P335L SNP widely exists in the human population, in patients with pancreatic cancer, and is race-dependent. The SNP is also present in selected human pancreatic cancer cell lines. In contrast to SSTR5 P335, overexpression of the SSTR5 L335 variant resulted in cellular proliferation and PDX-1 overexpression in human pancreatic cancer cells. Its overexpression blocked the inhibitory effect of an SSTR5-specific analog on human pancreatic cancer cell proliferation and on glucose-stimulated insulin secretion from mouse insulinoma cells. These data suggest that SSTR5 P335L is a hypofunctional protein with a potentially harmful effect on function, as well as potential latent effect, and therefore it could affect the clinical response to somatostatin analog therapy for patients with pancreatic cancer.
Michael E. DeBakey Department of Surgery, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA.
Guisheng
G
Zhou
Marie-Claude
MC
Gingras
Shi-He
SH
Liu
Donghui
D
Li
Zhijun
Z
Li
Robbi L
RL
Catania
Kelly M
KM
Stehling
Min
M
Li
Giovanni
G
Paganelli
Richard A
RA
Gibbs
Francesco J
FJ
Demayo
William E
WE
Fisher
F Charles
FC
Brunicardi
D000230:Adenocarcinoma / Q000208:ethnology / Q000235:genetics*; D001741:Black or African American / Q000235:genetics; D000483:Alleles; D000818:Animals; D000911:Antibodies, Monoclonal / Q000235:genetics; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D003062:Codon / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics; D005787:Gene Frequency; D005838:Genotype; D006630:Hispanic or Latino / Q000235:genetics; D006801:Humans; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D051379:Mice; D008807:Mice, Inbred BALB C; D010190:Pancreatic Neoplasms / Q000208:ethnology / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D017481:Receptors, Somatostatin / Q000235:genetics* / Q000276:immunology; D044465:White People / Q000235:genetics
D000911:Antibodies, Monoclonal; D003062:Codon; D007328:Insulin; D017481:Receptors, Somatostatin; C094573:somatostatin receptor 5
Nature. 2010 Apr 1;464(7289):674-5
20360716
Genes Dev. 2006 Jun 1;20(11):1435-40
16751181
Aliment Pharmacol Ther. 2010 Jan 15;31(2):169-88
19845567
Cancer Res. 2006 Apr 15;66(8):4149-58
16618736
Cancer. 2011 Jul 1;117(13):2863-72
21692047
Front Neuroendocrinol. 1999 Jul;20(3):157-98
10433861
Gastroenterology. 1988 Sep;95(3):760-3
2899530
J Surg Res. 1998 Apr;76(1):57-60
9695740
J Surg Res. 2005 Nov;129(1):64-72
16026801
Surgery. 1998 Aug;124(2):254-8; discussion 258-9
9706146
Mol Endocrinol. 1992 Oct;6(10):1585-97
1448113
Mol Psychiatry. 2002;7(7):745-54
12192619
Hum Pathol. 2006 Sep;37(9):1162-8
16938521
Cancer Res. 2003 Jul 1;63(13):3593-7
12839946
Curr Med Chem. 2007;14(16):1745-52
17627512
APMIS. 2008 Jun;116(6):491-8
18754323
Mol Endocrinol. 2008 Mar;22(3):676-88
18096696
Pancreas. 2003 Apr;26(3):e67-73
12657967
Am J Hum Genet. 2005 Jun;76(6):950-66
15830322
J Natl Cancer Inst. 2006 Apr 5;98(7):491-8
16595785
Biochem Biophys Res Commun. 1996 Dec 24;229(3):746-51
8954967
J Biol Chem. 2006 Jul 14;281(28):19156-71
16690617
World J Gastroenterol. 2006 Apr 7;12(13):2011-5
16610049
Semin Surg Oncol. 1998 Jul-Aug;15(1):57-61
9671958
J Endocrinol Invest. 2004 Nov;27(10):937-42
15762041
Biochem J. 1996 Jan 15;313 ( Pt 2):495-502
8573083
Mol Pharmacol. 1993 Aug;44(2):385-92
8102785
Nature. 2004 Sep 16;431(7006):371-8
15372045
J Biol Chem. 1997 May 2;272(18):11986-93
9115263
Mol Cell Endocrinol. 2008 May 14;286(1-2):230-7
18359151
Cancer Gene Ther. 2000 Jan;7(1):97-106
10678362
World J Surg. 2009 Apr;33(4):612-4
19083052
Gut. 2004 Mar;53(3):323-30
14960508
Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):251-5
1346068
Diabetes. 1996 Dec;45(12):1826-31
8922372
Pancreas. 2004 Mar;28(2):109-20
15028942
Nat Genet. 2003 Mar;33 Suppl:228-37
12610532
J Clin Endocrinol Metab. 2001 May;86(5):2161-9
11344221
Science. 1973 Jan 5;179(4068):77-9
4682131
Endocrinology. 2008 Sep;149(9):4736-46
18566118
Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1644-50
19423539
Endocr Rev. 1995 Aug;16(4):427-42
8521788
Ann Surg. 2004 Nov;240(5):875-84
15492571
Front Biosci. 2008 Jan 01;13:822-40
17981589
J Biol Chem. 1992 Oct 5;267(28):20422-8
1328199
J Endocrinol Invest. 2009 Apr;32(4):360-9
19636207
Mol Endocrinol. 1999 Jan;13(1):82-90
9892014
J Surg Res. 2008 Jan;144(1):8-16
17583748
Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9015-20
8799146
FEBS Lett. 2005 Jun 6;579(14):3107-14
15919085
World J Surg. 2005 Mar;29(3):334-8
15706433
Int J Cancer. 2003 Nov 1;107(2):238-43
12949800
Mol Cell Endocrinol. 2008 May 14;286(1-2):169-79
18375050
Pancreas. 2008 Aug;37(2):210-20
18665085